Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
November 1st 2017
Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.